Assessing the clinical benefit of nuclear matrix protein 22 in the surveillance of patients with nonmuscle-invasive bladder cancer and negative cytology: a decision-curve analysis.
Saved in:
| Title: | Assessing the clinical benefit of nuclear matrix protein 22 in the surveillance of patients with nonmuscle-invasive bladder cancer and negative cytology: a decision-curve analysis. |
|---|---|
| Authors: | Shariat SF (AUTHOR), Savage C (AUTHOR), Chromecki TF (AUTHOR), Sun M (AUTHOR), Scherr DS (AUTHOR), Lee RK (AUTHOR), Lughezzani G (AUTHOR), Remzi M (AUTHOR), Marberger MJ (AUTHOR), Karakiewicz PI (AUTHOR), Vickers AJ (AUTHOR), Shariat, Shahrokh F1 (AUTHOR), Savage, Caroline (AUTHOR), Chromecki, Thomas F (AUTHOR), Sun, Maxine (AUTHOR), Scherr, Douglas S (AUTHOR), Lee, Richard K (AUTHOR), Lughezzani, Giovanni (AUTHOR), Remzi, Mesut (AUTHOR), Marberger, Michael J (AUTHOR) |
| Source: | Cancer (0008543X). 7/1/2011, Vol. 117 Issue 13, p2892-2897. 6p. |
| Database: | Academic Search Ultimate |
Be the first to leave a comment!
